A large study of patients with mild cognitive impairment revealed that results from cognitive tests and brain scans can work as an early warning system for the subsequent development of Alzheimer's disease.

A new study published in the July issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended.

With the most recent release of data from the National Oncologic PET Registry (NOPR), researchers may have reached the moment of critical mass by confirming the effectiveness of positron emission tomography (PET) in the monitoring of tumor activity across a wide range of cancers.

Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Annual Meeting. As a result, unnecessary surgeries could be reduced, which would also lower morbidity rates and postoperative complications for ovarian cancer patients.

Positron emission tomography (PET) could be an important tool for identifying non-Hodgkin's lymphoma patients who are likely to respond well to treatment with 90 ibritumomab tiuxetan (IT)—the first radioimmunotherapy treatment approved for use by the U.S. Food and Drug Administration, said researchers at SNM's 55th Annual Meeting.

A promising new technique has been developed that will enable more accurate non-invasive positron emission tomography (PET) imaging of new cells injected into the body, according to researchers at SNM's 55th Annual Meeting. The new technique, which involves engineering antibody fragments to act as reporter genes—or markers that signal cells of interest for PET imaging purposes—could significantly advance the study of genetically engineered cells to treat diseases.

Evaluations of the first-ever prototype positron emission tomography (PET) brain scanner that uses semiconductor detectors indicate that the scanner could advance the quality and spatial resolution of PET imaging, according to researchers at SNM's 55th Annual Meeting. The prototype scanner already has proven successful in better characterizing partial epilepsy and nasopharyngeal cancer.

The first patient scans from a custom-built scanner combining positron emission tomography (PET) and computed tomography (CT) technologies indicate that these scans could significantly improve breast cancer imaging capabilities and lead to more targeted treatment options, according to researchers at SNM's 55th Annual Meeting.

Researchers at UCLA's Jonsson Comprehensive Cancer Center have modified a common chemotherapy drug to create a new probe for Positron Emission Tomography (PET), an advance that will allow them to model and measure the immune system in action and monitor response to new therapies.

According to a study of data from the National Oncologic PET Registry (NOPR) published online in the Journal of Clinical Oncology (JCO) on March 24th, clinicians changed the intended care of more than one in three cancer patients as the results of FDG-PET scan findings.

Using a combination of positron emission tomography (PET) and computed tomography for radiation therapy treatment planning in head and neck carcinoma patients provides for excellent, local and regional disease control when compared to CT alone, according to a study in the March 1 issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

Researchers involved in a large, multi-institutional study comparing the accuracy of positron emission tomography (PET) and computed tomography (CT) in the characterization of lung nodules found that PET was far more reliable in detecting whether or not a nodule was malignant.